Chandran, Manju http://orcid.org/0000-0001-9119-8443
Alves, Ines
Carpenter, Thomas
Davis, Michelle
Hsiao, Edward C.
Petryk, Anna
Semler, Jorg Oliver
Sleiman, Marwan
Funding for this research was provided by:
Ipsen
AstraZeneca Rare Disease
Kyowa Kirin
Article History
Received: 20 March 2023
Accepted: 11 May 2023
First Online: 9 June 2023
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: MC has received honoraria for speaking and chairing engagements from Kyowa Kirin. TOC receives clinical trial research support through his institution from Ultragenyx for studies related to XLH and Osteogenesis Imperfecta. He has received consulting fees and honoraria from Alexion, Inozyme (Medical Advisory Board), Ipsen, Kyowa Kirin (Advisory Board), Ultragenyx, and Viridian. TOC serves in an unpaid capacity on the Medical Advisory Board for the FD/MAS Alliance, and the Scientific Advisory Boards of the XLH-Network, and Soft Bones (the US Hypophosphatasia Foundation). ECH receives clinical trial research support through his institution from Clementia Pharmaceuticals, an Ipsen Company, for studies related to FOP. He received prior clinical trials research support from Ultragenyx, Inc. for clinical trials research support through his institution for studies in osteogenesis imperfecta. ECH serves in an unpaid capacity on the Medical Advisory Board for the FD/MAS Alliance, on the Medical Registry Advisory Board of the International FOP Association, and on the International Clinical Council for FOP. AP is employee of and may own stock/options in Alexion, AstraZeneca Rare Disease. MS is an employee and shareholder of Ipsen. MD is a volunteer for the Rare Bone Disease Alliance Steering Committee. IA and JOS have no conflicts of interest.